Investors were pleased with biotech Jounce Therapeutics (NASDAQ: JNCE) on Tuesday. The FDA cleared Jounce's Investigational New Drug (IND) application for its pipeline cancer immunotherapy JTX-1811, one of the four pipeline drugs currently being developed by the company. This, in turn, is triggering a $25 million milestone payment from Gilead Sciences (NASDAQ: GILD), which holds the exclusive rights to develop and commercialize JTX-1811.
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting